Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg starts coverage of Telecom Plus at 'buy'

(Sharecast News) - Berenberg initiated coverage of Telecom Plus on Thursday with a 'buy' rating and 2,600p price target as it argued it was a "gem" that has "fallen through the cracks". The bank noted that through its Utility Warehouse (UW) brand, the business offers a range of energy, broadband, mobile, insurance and cashback card services to UK households and small businesses.

The company's subscription-style platform acts as a virtual service provider for essential household services for homes in the UK, it said.

"Customers can bundle multiple services together, creating a convenient multi-service offering that can achieve the best savings in the market, while also providing TEP with high value, long-term customers," Berenberg said.

"TEP has successfully grown the business through multiple macro environments and cycles to over 1.1m customers and today is the seventh-largest energy provider in the UK and the largest UK energy provider to have acquired all of its customers organically.

"However, in our view, this unique business is flying under many investors' radars."

Berenberg said its lack of peers means that Telecom Plus it is often incorrectly positioned and valued against other utility providers with much lower growth and return profiles.

"This creates an attractive proposal for investors: a predictable and highly cash-generative/high-return (over 30% ROCE) business with circa 10-15% customer growth per annum, trading in the wrong bucket."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.